The company Locus Biosciences is enrolling patients into the clinical trial investigating A Study of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Multi-drug Resistant Escherichia Coli (E. Coli) (ELIMINATE).
This is a Phase 2/3 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 550 patient portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.
The trial is designed to enroll Female 18 Years to 65 Years.
The study start date is July 13, 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05488340.